TABLE 2.
Subject ID | Drug | Daily Dose (mg) | Conversion Factor | LED (mg) | Total, LEDD (mg) |
1 | Stalevo | 375 | 1.33 | 499 | 699 |
Rasagiline | 1 | 100 | 100 | ||
Amantadine | 100 | 1 | 100 | ||
2 | Rytary | 170 | 0.6 | 102 | 602 |
Pramipexole | 3 | 100 | 300 | ||
Amantadine | 200 | 1 | 200 | ||
4 | Stalevo | 550 | 1.33 | 732 | 852 |
Rotigotine | 4 | 30 | 120 | ||
5 | Stalevo | 400 | 1.33 | 532 | 652 |
Rotigotine | 4 | 30 | 120 | ||
6 | Sinemet | 200 | 1 | 200 | 275 |
Sinemet CR | 100 | 0.75 | 75 | ||
7 | Sinemet | 300 | 1 | 300 | 300 |
We also show the conversion factors that lead to the LED calculation following Tomlinson et al. (2010) guidelines. Subject 3 is not reported since not currently treated with levodopa, dopamine agonists or other dopamine-interacting drugs.